Rhaeos CEO Shares Details About Wearable FlowSense Device
Earlier this year, Rhaeos won MedTech Innovator’s 2020 Global Competition. The award will help further the development of their wearable, noninvasive FlowSense device. In a recent conversation with Rhaeos CEO Anna Lisa Somera, Somera discussed the significance of the award and how FlowSense can improve the way hydrocephalus is managed.
Congratulations on winning the MedTech Innovator’s 2020 Global Competition award! What’s the significance of this award?
MedTech Innovator (MTI) is the largest global medical device-only accelerator and is sponsored by big industry players such as Johnson and Johnson, Olympus, Nipro, Baxter, and more. With the win, we took home $350,000 in cash plus Johnson and Johnson Labs (JLabs) space. This year, MTI had over 1,000 applicants and taking the top spot has been an enormous honor. It is the culmination of a great deal of hard work from the Rhaeos team in collaboration with a fantastic slate of advisors. Our biggest goal when participating in MTI was to really listen to the advisors and incorporate as much of their knowledge and wisdom as possible into our strategic plans. But to win the Grand Prize was beyond our wildest imagination. Additionally, to be the first female to take the top spot this makes the win even more meaningful.
What is FlowSense and how does it work?
Where did the idea for this device come about?
The idea behind the FlowSense device came about when Rhaeos Co-founder, Dr. John Rogers, and Northwestern Memorial Hospital neurosurgeon, Matthew Potts, connected to discuss the use of sensors as a better way to monitor treatment flow in hydrocephalus patients. Dr. Rogers, a world-renowned wearables inventor, and Louis Simpson and Kimberly Querrey, Professor of Materials Science and Engineering, Biomedical Engineering and Neurological Surgery at Northwestern, was intrigued by this potential application and looped me in. I worked in medical devices for 16 years, so when I heard about this opportunity, I hit the brakes on everything I was doing, knowing that this technology would become something exceptional. Then upon taking the helm, I recruited teammates from previous start-ups to which we participated. I wanted start-up veterans with battle scars. And it has paid off, as we continually hit our milestones primarily due to the team and its passion for our product.
When do you anticipate that the product will be available clinically? Are you currently pursuing clinical trials?
We anticipate that a great deal of the product development and clinical work will be funded through pending NSF and NIH grants in combination with investors in our current seed round. We plan to follow that with a Series A round to scale the device.